Preoperative levels of serum interleukin-6 in patients with hepatocellular carcinoma

Hepato-Gastroenterology

Volumn 58, Issue 110-111, 2011, Pages 1687-1693

  Pang, Xiong Hao ^a   Zhang, Jing Ping ^b   Zhang, Yao Jun ^a   Yan, Jing ^b   Pei, Xiao Qing ^a,b   Zhang, Ya Qi ^a   Li, Jin Qing ^a   Zheng, Limin ^a,b   Chen, Min Shan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Inflammatory cytokines; Interleukin 6; Tumor size

Indexed keywords

INTERLEUKIN 6;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE; TUMOR VOLUME;

EID: 83355174169     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: 10.5754/hge10799     Document Type: Article

References (14)

1. Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet 2003; 362:1907-1917. (Pubitemid 37518510)
2. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
3. Farazi PA, DePinho RA: Hepatocellular carcinoma pathogenesis: from genes to environment. Nat Rev Cancer 2006; 6:674-687. (Pubitemid 44286000)
4. Hoffmann A, Xia Y, Verma IM: Inflammatory tales of liver cancer. Cancer Cell 2007; 11:99-101. (Pubitemid 46209854)
5. Poon D, Anderson BO, Chen LT, et al.: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10:1111-1118.
6. Schafer ZT, Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest 2007; 117:3660-3663. (Pubitemid 350224077)
7. Tang Y, Kitisin K, Jogunoori W, et al.: Progenitor/stem cells give rise to liver cancer due to aberrant TGF-beta and IL-6 signaling. Proc Natl Acad Sci U S A 2008; 105:2445-2450. (Pubitemid 351520533)
8. Naugler WE, Sakurai T, Kim S, et al.: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317:121-124. (Pubitemid 47056470)
9. Porta C, De Amici M, Quaglini S, et al.: Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 2008; 19:353-358. (Pubitemid 351201719)
10. Zhang JP, Yan J, Xu J, et al.: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009; 50:980-989.
11. Galon J, Costes A, Sanchez-Cabo F, et al.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-1964. (Pubitemid 44498003)
12. Hsia CY, Huo TI, Chiang SY, et al.: Evaluation of interleukin-6, interleukin-10 and human hepatocyte growth factor as tumor markers for hepatocellular carcinoma. Eur J Surg Oncol 2007; 33:208-212.
13. Wong VW, Yu J, Cheng AS, et al.: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 2009; 124:2766-2770.
14. Nakagawa H, Maeda S, Yoshida H, et al.: Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 2009; 125:2264-2269.